SMT201900656T1 - Formulazioni di ketorolac pronte all'uso - Google Patents

Formulazioni di ketorolac pronte all'uso

Info

Publication number
SMT201900656T1
SMT201900656T1 SM20190656T SMT201900656T SMT201900656T1 SM T201900656 T1 SMT201900656 T1 SM T201900656T1 SM 20190656 T SM20190656 T SM 20190656T SM T201900656 T SMT201900656 T SM T201900656T SM T201900656 T1 SMT201900656 T1 SM T201900656T1
Authority
SM
San Marino
Prior art keywords
ready
ketorolac formulations
use ketorolac
formulations
ketorolac
Prior art date
Application number
SM20190656T
Other languages
English (en)
Italian (it)
Inventor
Joseph Pergolizzi
Alexander Mironov
Chad James Pickens
Douglas Giles Johnson
Original Assignee
Rtu Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rtu Pharmaceuticals Llc filed Critical Rtu Pharmaceuticals Llc
Publication of SMT201900656T1 publication Critical patent/SMT201900656T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SM20190656T 2010-10-21 2011-10-21 Formulazioni di ketorolac pronte all'uso SMT201900656T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40538410P 2010-10-21 2010-10-21
US201161481602P 2011-05-02 2011-05-02
EP11835216.0A EP2616064B1 (en) 2010-10-21 2011-10-21 Ready to use ketorolac formulations
PCT/US2011/057284 WO2012054831A2 (en) 2010-10-21 2011-10-21 Ready to use ketorolac formulations

Publications (1)

Publication Number Publication Date
SMT201900656T1 true SMT201900656T1 (it) 2020-01-14

Family

ID=45973506

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20190656T SMT201900656T1 (it) 2010-10-21 2011-10-21 Formulazioni di ketorolac pronte all'uso

Country Status (19)

Country Link
US (5) US9421191B2 (https=)
EP (3) EP4190327A1 (https=)
JP (1) JP6013346B2 (https=)
KR (4) KR20140012029A (https=)
CN (2) CN108703948A (https=)
CA (1) CA2814805C (https=)
CY (1) CY1122516T1 (https=)
DK (1) DK2616064T3 (https=)
ES (2) ES2753981T3 (https=)
HR (1) HRP20191994T1 (https=)
HU (1) HUE045889T2 (https=)
LT (1) LT2616064T (https=)
MX (1) MX346879B (https=)
PL (1) PL2616064T3 (https=)
PT (1) PT2616064T (https=)
RS (1) RS59526B1 (https=)
SI (1) SI2616064T1 (https=)
SM (1) SMT201900656T1 (https=)
WO (1) WO2012054831A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2616064T (lt) 2010-10-21 2019-11-25 Rtu Pharmaceuticals Llc Parengtos naudoti ketorolako kompozicijos
US10098872B1 (en) 2013-07-22 2018-10-16 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992484B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11559521B2 (en) * 2013-07-22 2023-01-24 William Bradley Worthington Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
US11992485B2 (en) 2013-07-22 2024-05-28 Hutchison Health, Llc Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN103830171B (zh) * 2014-03-04 2015-11-18 鲁南制药集团股份有限公司 一种酮咯酸氨丁三醇注射液及其制备方法
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
MY191574A (en) * 2015-02-10 2022-06-30 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
IT201600075246A1 (it) * 2016-07-19 2018-01-19 Jointherapeutics S R L Composizioni comprendenti una matrice polisaccaridica per il rilascio controllato di principi attivi.
EP4467600A3 (en) * 2017-05-10 2025-03-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
FR3101917B1 (fr) 2019-10-09 2022-07-15 Ifp Energies Now Système de refroidissement à radiateur unique
CN110812325B (zh) * 2019-11-13 2022-04-05 鲁南制药集团股份有限公司 一种提高酮咯酸氨丁三醇注射液存储稳定性的方法
CN119818450A (zh) * 2020-05-19 2025-04-15 南京海融医药科技股份有限公司 一种左酮咯酸的药物组合物及其制备方法
CN114159384B (zh) * 2021-02-07 2023-04-07 南京锐志生物医药有限公司 一种化学性质稳定的低刺激性酮咯酸氨丁三醇注射液
TWI857310B (zh) * 2021-06-24 2024-10-01 大陸商上海雲晟研新生物科技有限公司 酮咯酸胺丁三醇的液體組合物、其製備方法及應用
CN113384524B (zh) * 2021-07-05 2025-08-12 四川尚锐生物医药有限公司 一种稳定的酮咯酸氨丁三醇注射液的制备方法
CN114191384A (zh) * 2021-12-20 2022-03-18 成都倍特药业股份有限公司 一种即用型酮咯酸氨丁三醇和氢溴酸依他佐辛组合液体制剂
CN114432240A (zh) * 2022-03-04 2022-05-06 郑州市中心医院 一种稳定不刺激的酮咯酸氨丁三醇注射液及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US5214052A (en) 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
PT948965E (pt) 1997-07-11 2004-08-31 Toray Industries Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
WO2000057851A2 (en) 1999-03-26 2000-10-05 Pozen Inc. High potency dihydroergotamine compositions
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US20070049552A1 (en) 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20080317681A1 (en) 2003-07-11 2008-12-25 Petros Gebreselassie Compositions containing a stain removing complex, and methods of making and using the same
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
KR20070084211A (ko) * 2004-10-15 2007-08-24 유서홍 약제학적 화합물의 독성을 감소시키기 위한 방법 및 조성물
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
CN101257890B (zh) 2005-09-01 2012-10-31 巴克斯特国际公司 含有酸作为增溶剂的阿加曲班制剂
US20070142478A1 (en) 2005-12-21 2007-06-21 Erning Xia Combination antimicrobial composition and method of use
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
DOP2007000055A (es) * 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas
MX2008013405A (es) 2006-04-18 2009-03-09 Ekr Therapeutics Inc Composiciones farmaceuticas premezcladas listas para uso.
US20100010046A1 (en) 2006-06-12 2010-01-14 Ironwood Pharmaceuticals, Inc. Pharmaceutical formulation for parenteral administration
JP2009542665A (ja) 2006-06-29 2009-12-03 シェーリング コーポレイション 糖を含まない保存に安定な抗ヒスタミンシロップ
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080057023A1 (en) * 2006-08-29 2008-03-06 Chynn Emil W Oxygenated ophthalmic composition
US7589106B2 (en) 2006-09-27 2009-09-15 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
KR100836624B1 (ko) 2006-12-08 2008-06-10 한국전자통신연구원 가변 고속 푸리에 변환 장치 및 그 방법
US20080312154A1 (en) 2007-06-15 2008-12-18 Barbara Lee Peterlin Administration of adipocytokine and adiponectin for treating headache and methods of diagnosing headache by measuring adiponectin
CA2699172C (en) 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
WO2009087658A2 (en) * 2007-11-07 2009-07-16 Sun Pharma Advanced Research Company Limited Composition suitable for parenteral administration
JP5909750B2 (ja) 2007-11-13 2016-04-27 マリンクロット アイピー 低用量静脈内アセトアミノフェン
US20090239836A1 (en) 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US8956636B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
TWI397038B (zh) * 2008-11-05 2013-05-21 Au Optronics Corp 使用半源極驅動架構之顯示面板及其顯示資料供應方法
KR20190031592A (ko) * 2010-07-19 2019-03-26 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
EP2596112A4 (en) 2010-07-21 2015-01-21 Cumberland Pharmaceuticals Inc ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
LT2616064T (lt) 2010-10-21 2019-11-25 Rtu Pharmaceuticals Llc Parengtos naudoti ketorolako kompozicijos

Also Published As

Publication number Publication date
KR20200078541A (ko) 2020-07-01
MX2013004393A (es) 2014-09-12
US9421191B2 (en) 2016-08-23
PT2616064T (pt) 2019-11-06
ES2753981T3 (es) 2020-04-15
CA2814805C (en) 2021-11-02
HUE045889T2 (hu) 2020-01-28
WO2012054831A2 (en) 2012-04-26
US20180280351A1 (en) 2018-10-04
US9962371B2 (en) 2018-05-08
EP4190327A1 (en) 2023-06-07
CN103167800A (zh) 2013-06-19
US11116750B2 (en) 2021-09-14
JP2013543843A (ja) 2013-12-09
KR102307601B1 (ko) 2021-09-30
ES2933198T3 (es) 2023-02-02
CA2814805A1 (en) 2012-04-26
KR20190085561A (ko) 2019-07-18
HRP20191994T1 (hr) 2020-02-07
EP3632432A1 (en) 2020-04-08
KR20180119610A (ko) 2018-11-02
WO2012054831A3 (en) 2012-06-07
JP6013346B2 (ja) 2016-10-25
EP2616064B1 (en) 2019-08-07
RS59526B1 (sr) 2019-12-31
CN108703948A (zh) 2018-10-26
EP2616064A4 (en) 2016-07-20
US20190105301A1 (en) 2019-04-11
MX346879B (es) 2017-04-03
KR20140012029A (ko) 2014-01-29
PL2616064T3 (pl) 2020-02-28
DK2616064T3 (da) 2019-11-11
SI2616064T1 (sl) 2019-12-31
CY1122516T1 (el) 2021-01-27
US20120101142A1 (en) 2012-04-26
US20170007575A1 (en) 2017-01-12
EP3632432B1 (en) 2022-09-14
EP2616064A2 (en) 2013-07-24
US20220023260A1 (en) 2022-01-27
US10278959B2 (en) 2019-05-07
KR102114568B1 (ko) 2020-05-22
LT2616064T (lt) 2019-11-25

Similar Documents

Publication Publication Date Title
SMT201900656T1 (it) Formulazioni di ketorolac pronte all'uso
SMT201400055B (it) Composti di tioacetato, composizioni e metodi d'uso
DK2648809T3 (da) Naturlige formuleringer
EP2543356A4 (en) SUN PROTECTION COMPOSITION
EP2581431A4 (en) AEROSOL COMPOSITION
HRP20181347T1 (hr) Formulacije dvoslojne tablete
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
IL225245A0 (en) Gel compositoin
BRPI0814188A2 (pt) Formulações
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
EP2344522A4 (en) COMBINATION ADJUVANT FORMULATION
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI1008215A2 (pt) "composição azeotrópica"
GT201200303A (es) Formulaciones farmacéuticas
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
ITMI20080003A1 (it) Composizioni per uso oftalmico
BR112013014612A2 (pt) composições moc
BR112013003530A2 (pt) ''produto farmacêutico, kit, uso e preparações''
EP2934694C0 (en) ANTI-PLAQUE ORAL COMPOSITIONS
BR112012031861A2 (pt) uso de 5a-androstano (alquil)-3b, 5, 6b-triol
FR2957252B1 (fr) Composition cosmetique
EP2623092A4 (en) COSMETIC COMPOSITION
BRPI1011036A2 (pt) uso
DK2170292T3 (da) Atazanavirholdige sammensætninger i tabletform
EP2207567A4 (en) IMMUNOGENIC FORMULATIONS